The most controversial points concern the treatment of an aged patient with hypogonadism, in particular if obese or with cardiovascular comorbidities, mainly as far as safety of the therapy, total testosterone cut-off value suggested to start replacement therapy and PSA alarm value for the risk of prostatic carcinoma during testosterone replacement therapy are concerned. The gene discussed is PROS1; the disease is hypogonadism.